Qureight accelerates drug development at key decision points through data curation and AI-powered decision making. We work with biopharma, contract research organisations, and hospitals to curate data and get the best drugs approved fast.
We are currently focused on lung and heart disease which, by every metric (including drug development time, diagnostic cost and drug reimbursement spend), is larger than all cancer combined.
Interstitial lung diseases (ILDs) are a group of diseases which cause scarring and damage to the lung tissue itself. They can be difficult to diagnose and monitor and clinical trial development pathways can be complex. They encompass over 200 individual diseases including Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis and Hypersensitivity Pneumonitis. Drug treatment can vary from steroids to immunosuppression to antifibrotics. Some patients may have associated pulmonary hypertension and others may need a lung transplant.
Pulmonary Hypertension (PH) is an umbrella term for a group of conditions which cause an increased pressure in the heart/lung vascular circuit. This pressure increase can be caused by a range of diseases including autoimmune diseases, problems with the lungs or the heart itself, blood clots or can be of unknown cause. Monitoring it can be hard, needing invasive procedures to pass tubes into the blood vessels to directly measure the pressures. A new range of drugs to treat these diseases are being developed by many different biopharma companies.
Lung cancer is one of the most common and fatal types of cancer. It can be associated with smoking, genetics or industrial exposures. The cancer can be primary, which starts in the lung, or secondary, which has spread to the lungs from other parts of the body. Treatments include surgery, radiotherapy, chemotherapy and targeted immunotherapy. Some of the newer medications can cause damage to the lung tissue surrounding the cancer as a side effect of the treatment.
The collaboration with Qureight supports AstraZeneca’s aim to harness data and technology to push the boundaries of science and deliver life-changing medicines to patients. Qureight’s AI technology allows us to investigate outcomes in multiple respiratory diseases, create new endpoints and improve patient selection for clinical trials in diseases such as Idiopathic Pulmonary Fibrosis.
Vicore’s work with Qureight has highlighted information from our data that we otherwise wouldn’t have had access to. Following this analysis, we now know which patients are most likely to improve with C21, and how. This insight will prove invaluable as we continue our work to provide a much-needed new IPF treatment.
The Qureight team helped smooth the transition of data transfer by effectively and efficiently setting up all the necessary steps prior to the transfer (creating a storing data location, providing access, providing input on data organization, etc) and collectively working with Clario to resolve any questions in a timely manner.
